...

CCO Treatment Updates

Answering the Questions: Clinical Considerations in the Use of Integrase Inhibitors

Answering the Questions: Clinical Considerations in the Use of Integrase Inhibitors

Module 1 of 2

Faculty:

William G. Powderly, MDPaul E. Sax, MDJonathan M. Schapiro, MD
  • William G. Powderly, MD
  • Paul E. Sax, MD
  • Jonathan M. Schapiro, MD

CREDIT INFORMATION

Release Date: June 12, 2009

Expiration Date: June 11, 2010


Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

Status: The activity is not currently available for credit.
Begin the Module

William G. Powderly, MD; Paul E. Sax, MD; and Jonathan M. Schapiro, MD, address pressing questions regarding the use of HIV integrase inhibitors in clinical practice.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recount strategies to maximize the likelihood of achieving virologic suppression with integrase inhibitors in treatment-experienced patients
  • Describe situations in which integrase inhibitors may be considered in first-line therapy
  • Discuss considerations when switching an agent in a virologically suppressive regimen to raltegravir
  • Explain the clinical relevance of integrase inhibitor resistance seen upon virologic failure

Abstract

Faculty Responses to Additional Questions on the Use of Integrase Inhibitors in Clinical Practice

Module 2 of 2

Faculty:

William G. Powderly, MDPaul E. Sax, MDJonathan M. Schapiro, MD
  • William G. Powderly, MD
  • Paul E. Sax, MD
  • Jonathan M. Schapiro, MD

CREDIT INFORMATION

Release Date: December 10, 2009

Expiration Date: December 09, 2010


Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Status: Please log in to view status
Begin the Module

William G. Powderly, MD; Paul E. Sax, MD; and Jonathan M. Schapiro, MD, answer the most compelling questions posed by readers on the use of integrase inhibitors in clinical practice.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recount drug-drug interactions associated with the use of raltegravir
  • Describe adverse events associated with integrase inhibitors
  • Discuss the feasibility of using raltegravir in special populations, such as pediatric patients and pregnant women
  • Recount data on the investigational integrase inhibitor S/GSK1349572

Abstract

CCO Slideset

Answering the Questions: Clinical Considerations in the Use of Integrase Inhibitors

Download the Slideset


In this downloadable slideset, Jonathan M. Schapiro, MD, presents data on the most pressing questions regarding the use of HIV integrase inhibitors in clinical practice.


Format: Microsoft PowerPoint (.ppt) | File size: 1.59 MB | Date posted: 6/22/2009


Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grant provided by:

Educational grants support only the CME-certified components of this program.